skin cancer
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
Skin Cancer Dx Firm Speclipse Raises Nearly $8M to Expand Business
The South Korean company plans to use the funding to develop its laser spectroscopy and artificial intelligence technologies for blood analysis.
Castle Biosciences Q2 Revenues Rise 79 Percent
The company said it delivered 70 percent more DecisionDx-Melanoma test results year over year, and that the total number of all tests delivered more than doubled.
Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic
The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
May 11, 2021
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Mar 5, 2021
DermTech Q4 Revenues Up 31 Percent
Mar 9, 2020
Nov 11, 2019
Castle Biosciences Q3 2019 Revenues Quadruple
Sep 3, 2019
Castle Biosciences Q2 Revenues Up 168 Percent
Jul 25, 2019
Castle Bio Prices IPO at $16 per Share
Sep 26, 2018
Proscia Raises $8.3M in Series A Round
Jul 13, 2018
Apr 2, 2018
Feb 21, 2018